AMRI acquires Gadea Pharmaceutical Group

Published: 17-Jul-2015

Acquisition of API portfolio establishes a European base for sales and operations and significantly increases AMRI's presence in non-US markets

AMRI has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately held company located in Valladolid, Spain, specialising in technically complex active pharmaceutical ingredients (APIs) and finished drug products.

The purchase price was US$174m, including the issuance of 2.2 million shares of common stock to Gadea's owners, valued at $43.8m, with the balance paid in cash and through the assumption of existing debt.

‘The acquisition of Gadea marks another milestone in our company's path towards becoming the pre-eminent supplier of custom and complex drug development services and product to both the branded and generic pharmaceutical industry,’ said William S. Marth, AMRI's President and Chief Executive Officer. ‘This mutually beneficial transaction presents an exciting opportunity for our two companies that builds upon our growth, adding a strong portfolio of complex API that will augment our existing capabilities and services, and new customer relationships that will extend our global reach.’

Strategic benefits of the transaction include

  • Gadea's Crystal Pharma division significantly expands AMRI's marketable API portfolio and squarely positions the company as a source of speciality and generic APIs
  • Gadea's portfolio further extends AMRI's API development and manufacturing capabilities in steroids and hormones, providing the company with a comprehensive steroid offering
  • Acquisition augments AMRI's sterile drug product offerings with the addition of ophthalmic and parenteral suspension dosage forms and prefilled syringe and lyophilisation capability
  • Establishes a strong European base for sales and operations and significantly increases AMRI's presence into non-US markets.

‘For Gadea, this transaction will build on our company's proud past and position it for a powerful future,’ said Gerardo Gutierrez, CEO of Gadea. ‘Our capabilities in technically challenging API and diverse customer base are highly complementary to AMRI. With this combination, we achieve our goal of being a comprehensive provider of steroid APIs and gain access to the US market.’

Gadea operates a highly regarded API and finished dose development and manufacturing business with 2014 revenues of approximately $83m and 2014 adjusted EBITDA of approximately $17m.

You may also like